feder judg presid multidistrict litig regard claim babi
powder caus ovarian cancer limit two key plaintiff expert wit
present juri judg place restrict theori plaintiff expert
present contrast rule limit testimoni expert
thu think decis favor
daubert decis made district judg freda wolfson chief judg
district new jersey releas monday believ rule four key
point benefit first judg wolfson determin opinion
plaintiff key biolog expert dr ghassen sa talc use caus ovarian cancer
unsupport find studi unreli conclus second
plaintiff asbesto test expert dr william longo testifi result
polar light microscopi due reliabl reproduc issu judg cite
test method third dr longo testifi women use talc
expos signific amount asbesto judg said fail provid scientif
support use talc product caus either exposur signific exposur
asbesto final plaintiff offer juri theori inhal talc
caus ovarian cancer due littl support provid expert theori
believ matter epidemiolog posit comfort
key plaintiff wit limit share juri
believ argument heavili focus epidemiologist strength
associ talc ovarian cancer larg scale studi argument
think difficult plaintiff convey juri evidenc recent
juri decis st loui involv claim asbesto taint talc saw clear
wrongdo case number furthermor restrict
abil bring forth addit expert feel compani well posit deliv
similar verdict term next step suspect may time trial
kick includ delay pandem
jama studi find signific associ talc use ovarian cancer
previous note studi earli jama find statist
signific associ talc use feminin hygien ovarian cancer studi
pool studi prospect cohort key find hazard
ratio associ self-report ever use vs never use powder
genit area incid ovarian cancer ci
pleas see page report import disclosur
normal period improv fundament combin pharma md consum
franchis continu drive core revenue/ep growth acceler ex fx/olysio
headwind sustain mid-singl digit top-lin organ growth normal period
driven pharma industri lead perform improv medic devic
consum divis
pharma cc revenu growth
blockbust asset continu
bolster strong pipelin
medic devic see declin near
term start
consum acceler lsd growth
report ep growth
growth peer
medic devic reacceler
consum return msd growth
deeper impact remicad biosimilar
medic devic return
competit market growth rate
impact greater expect
pharma pipelin fail deliv near-term
growth opportun off-set remicad
consum margin growth
johnson johnson one world largest diversifi health care compani
offer product world-wide three major busi divis pharma medic
devic diagnost consum product one four compani
aaa credit rate give tremend amount flexibl debt instrument
provid compani unparallel buy sell opportun market
environ consist oper compani locat countri
top three prioriti sharehold dividend judici a/l across
three divis share repurchas elimin dilut compani intend
maintain industry-lead dividend pay-out ratio level higher
updat price reflect recent stock momentum
remain one defens name coverag univers suspect investor
sentiment continu posit pharma crown jewel franchis
resili busi persist headwind medic devic unit
impact rip band-aid earn
call set rel low bar elect procedur volum expect
similar everi name coverag univers durat
headwind includ potenti second wave remain biggest risk thesi
share current trade turn discount larg cap median
forward price-to-earnings multipl cash ep basi believ share deserv
trade less discount particularli consid elect procedur headwind face
devic intens product portfolio jnj rel limit exposur medic devic
unit repres revenu base assign multipl cash
ep estim exclud intang amort combin multipl
ebitda estim yield new blend price target
compani report thomson eikon cowen compani
year end decemb end decemb end decemb revenu good gross amort interest interest net interest incom incom incom tax incom tax incom restructur non-recur gain incom gaap net incom incl ep incl amort restructur non-recur charg dilut share margin analysisgross analysistot cowen
compani report thomson eikon cowen compani
good gross interest interest net interest incom incom incom tax incom tax incom restructur non-recur charg ep net incom ex ep incl amort restructur non-recur charg dilut share analysisgross incom cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
drug patent expir pharma pipelin price procedur volum risk
med devic failur bring consum product back market follow product
withdraw impact busi
